VISIBLE
Supports United Kingdom studies on coronary microvascular disease in women and translation into clinical care.
VISIBLE is a $55 million program co-funded by Wellcome Leap, Pivotal Ventures, and the British Heart Foundation that targets coronary microvascular disease (CMD) in women — a condition currently diagnosed and effectively treated in fewer than 1% of affected patients. The program's stated goal is to increase the proportion of women receiving effective CMD diagnosis and treatment from under 1% to mo…
Diagnosis and treatment of coronary microvascular disease in women, with the goal of increasing the proportion receiving effective care from under 1% to over 80%.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline